IMPULSIVE AGGRESSION--BIOLOGIC AND TREATMENT CORRELATES

描述(改编自申请人的摘要)：在各种 社会学、心理学和生物遗传因素与冲动、 相对于有预谋的，人类的侵略，最一致的生物 因素似乎是中枢5-羟色胺(5-羟色胺)的减少 神经传递。5-羟色胺在冲动性攻击调节中的作用 行为被认为是由于它在神经元抑制中的作用，通过 它约束行为行为，以回应外在(或内在) 令人厌恶的刺激或挑衅。在这个配方中，5-羟色胺起到了 限制个人攻击刺激对象和其他 神经系统(如儿茶酚胺)调节检测和/或 对令人厌恶的刺激的反应。在这个时候，几乎没有 对特定的5-羟色胺受体亚系统的这种作用的认识 儿茶酚胺，如去甲肾上腺素，在调节 这些行为。 在首席调查员的RSDA(第二级)申请续签中， 私隐专员公署建议进行更广泛和系统的研究 5-羟色胺-1a、5-羟色胺-2a/2c与α-2去甲肾上腺素功能的关系 和冲动性攻击和自杀行为的综合指数 人格障碍(PD)研究对象。此外，私家侦探计划扩大他的 阿司匹林抗侵袭性临床药物试验研究 氟西汀进行9个月的持续治疗和复发/缓解 研究对象为帕金森病患者。这一领域反攻击性的新方向 疗效由氟西汀/认知-行为相结合表示 对男性配偶施虐者的治疗试验。在当前的发展中， 格兰特，冲动攻击性意志障碍的可靠标准 允许进一步的工作(即，家庭研究、DNA多态研究、 流行病学调查)，以检验结构效度的全谱 作为临床实体的冲动攻击性行为。要实施的技能 这些研究和其他研究将在未来五年内获得，如果这 RSDA奖。

DESCRIPTION (Adapted from applicant's abstract): Among the various sociologic, psychologic, and biogenetic factors associated with impulsive, as opposed to premeditated, human aggression, the most consistent biological factor appears to be a reduction in central serotonergic (5-HT) neurotransmission. 5-HT's role in the regulation of impulsive aggressive behavior is thought to arise from its role in neuronal inhibition, through which it constrains behavioral action in response to an outward (or inward) aversive stimulus or provocation. In this formulation, 5-HT acts to restrain the individual from assaulting the object of stimulus and other neuronal systems (e.g., catecholamines) modulate the detection of, and/or the response to, the aversive stimulus. At this time, there is little knowledge regarding this role of specific 5-HT receptor subsystems and of the role of catecholamines, such as norepinephrine, in the mediation of these behaviors. In this renewal of the Principal Investigator's RSDA (Level II) Application, the PI proposes to conduct expanded and systematic studies regarding the relationship between indices of 5-HT-1a, 5-HT-2a/2c, and alpha-2 NE function and comprehensive indices of impulsive aggressive and suicidal behaviors in personality disorder (PD) subjects. In addition, the PI plans to expand his clinical drug trial research regarding the antiaggressive efficacy of Fluoxetine by conducting a nine-month continuation and relapse/remission study in PD subjects. A new direction in this area of antiaggressive efficacy is represented by a combined Fluoxetine/Cognitive-Behavioral treatment trial in male spouse abusers. The development, during the current grant, of reliable criteria for a disorder of Impulsive Aggression will allow further work (i.e., Family Study, DNA Polymorphism Study, Epidemiologic Survey) to test the full spectrum of construct validity for impulsive aggressive behavior as a clinical entity. The skills to implement these and other studies will be acquired during the next five years if this RSDA award.